Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Impact of S-1 on the survival of patients with advanced pancreatic cancer.

Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Tateishi K, Toda N, Tada M, Omata M, Koike K.

Pancreas. 2010 Oct;39(7):989-93. doi: 10.1097/MPA.0b013e3181d91936.

PMID:
20467352
2.

Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.

Nakai Y, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M, Omata M, Koike K.

Jpn J Clin Oncol. 2010 Aug;40(8):774-80. doi: 10.1093/jjco/hyq059. Epub 2010 May 12.

PMID:
20462979
3.

S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.

Todaka A, Fukutomi A, Boku N, Onozawa Y, Hironaka S, Yasui H, Yamazaki K, Taku K, Machida N, Sakamoto T, Tomita H.

Jpn J Clin Oncol. 2010 Jun;40(6):567-72. doi: 10.1093/jjco/hyq005. Epub 2010 Feb 26.

PMID:
20189975
4.

Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.

Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O.

Cancer Chemother Pharmacol. 2011 Feb;67(2):249-54. doi: 10.1007/s00280-010-1311-3. Epub 2010 Mar 30.

PMID:
20352216
5.

A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.

Kobayashi S, Ueno M, Ohkawa S, Andou T, Kameda R, Yamamoto N, Morinaga S.

Jpn J Clin Oncol. 2012 Sep;42(9):800-6. doi: 10.1093/jjco/hys102. Epub 2012 Jul 23.

PMID:
22826349
6.

Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H, Sueda T.

J Gastrointest Surg. 2009 Jan;13(1):85-92. doi: 10.1007/s11605-008-0650-4. Epub 2008 Aug 13.

PMID:
18704593
7.

Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.

Kawashima H, Itoh A, Ohno E, Nakamura M, Miyahara R, Ohmiya N, Hara K, Kanamori A, Itoh T, Taki T, Hirai T, Hashimoto S, Takeda K, Goto H, Hirooka Y.

Cancer Chemother Pharmacol. 2011 Sep;68(3):677-83. doi: 10.1007/s00280-010-1531-6. Epub 2010 Dec 5.

PMID:
21132496
8.

Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.

Kurihara T, Kogo M, Ishii M, Yoneyama K, Kitamura K, Shimada K, Shimizu S, Yoshida H, Kiuchi Y.

Hepatogastroenterology. 2015 Mar-Apr;62(138):478-84.

PMID:
25916086
9.

Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy.

Hosokawa A, Sugiyama T, Ohtsu A, Doi T, Hattori S, Kojima T, Yano T, Minashi K, Muto M, Yoshida S.

J Gastroenterol. 2007 Jul;42(7):533-8. Epub 2007 Jul 25.

PMID:
17653648
10.

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.

Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E.

Cancer Chemother Pharmacol. 2009 Jan;63(2):313-9. doi: 10.1007/s00280-008-0741-7. Epub 2008 Apr 9.

PMID:
18398614
11.

Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.

Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, Tawada K, Imagumbai T, Araki H, Sakai M, Hatano K, Kawakami H, Uno T, Ito H, Yokosuka O.

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):119-25. doi: 10.1016/j.ijrobp.2010.01.027. Epub 2010 Jun 3.

PMID:
20605363
12.

Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.

Li Y, Sun J, Jiang Z, Zhang L, Liu G.

J Chemother. 2015 Aug;27(4):227-34. doi: 10.1179/1973947815Y.0000000013. Epub 2015 Mar 20.

PMID:
25790948
13.

Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T.

Ann Surg. 2009 Dec;250(6):950-6.

PMID:
19953713
14.

[A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer].

Egawa T, Ohashi M, Ito Y, Mihara K, Takahashi T, Hayashi S, Nagashima A.

Gan To Kagaku Ryoho. 2009 Nov;36(12):2422-4. Japanese.

PMID:
20037443
15.

Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.

Aoyama T, Murakawa M, Katayama Y, Shiozawa M, Ueno M, Morimoto M, Yoshikawa T, Rino Y, Masuda M, Morinaga S.

Hepatogastroenterology. 2015 Mar-Apr;62(138):472-7.

PMID:
25916085
16.

Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.

Mar├ęchal R, Demols A, Gay F, De Maertelaere V, Arvanitaki M, Hendlisz A, Van Laethem JL.

Oncology. 2007;73(1-2):41-51. doi: 10.1159/000120627. Epub 2008 Mar 11.

PMID:
18334830
17.

A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1.

Morizane C.

Jpn J Clin Oncol. 2007 Dec;37(12):973. doi: 10.1093/jjco/hym146. No abstract available.

PMID:
18211987
18.

S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.

Okabayashi T, Shima Y, Iwata J, Morita S, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, Kosaki T, Kobayashi M, Hanazaki K.

World J Surg. 2014 Nov;38(11):2986-93. doi: 10.1007/s00268-014-2703-z.

PMID:
25104544
19.

Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.

Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Hagihara A, Iwasa S, Kojima Y.

Jpn J Clin Oncol. 2008 Nov;38(11):755-61. doi: 10.1093/jjco/hyn098. Epub 2008 Oct 8.

PMID:
18845521
20.

S-1 monotherapy in patients with advanced biliary tract cancer.

Sasaki T, Isayama H, Yashima Y, Yagioka H, Kogure H, Arizumi T, Togawa O, Matsubara S, Ito Y, Nakai Y, Sasahira N, Hirano K, Tsujino T, Tada M, Kawabe T, Omata M.

Oncology. 2009;77(1):71-4. doi: 10.1159/000226214. Epub 2009 Jun 26.

PMID:
19556812

Supplemental Content

Support Center